<DOC>
	<DOCNO>NCT02834403</DOCNO>
	<brief_summary>This Phase Ib study assess maximum tolerate dose ( MTD ) dose-limiting toxicity L-NMMA combine docetaxel refractory locally advance metastatic triple negative breast cancer patient . The study conduct two stage . Stage 1 study determine MTD L-NMMA combine 75 mg/m2 docetaxel . Stage 2 study determine MTD L-NMMA combine 60 mg/m2 docetaxel . Five dose level L-NMMA ( 5 , 7.5 , 10 , 12.5 , 15 mg/kg ) investigate stage 1 . The start dose L-NMMA 7.5 mg/kg . As patient accrue , standard Bayesian model average continual reassessment method ( CRM ) approach use determine appropriate L-NMMA dosage . In stage 2 , start dose one dose level MTD determine stage 1 . Again CRM use determine appropriate L-NMMA dosage .</brief_summary>
	<brief_title>L-NMMA Plus Docetaxel Refractory Locally Advanced Metastatic Triple Negative Breast Cancer Patients</brief_title>
	<detailed_description>This Phase Ib study assess maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) L-NMMA combine docetaxel refractory locally advance metastatic triple negative breast cancer patient . The study conduct two stage . Stage 1 study determine MTD L-NMMA combine 75 mg/m2 docetaxel . Stage 2 study determine MTD L-NMMA combine 60 mg/m2 docetaxel . Five dose level L-NMMA ( 5 , 7.5 , 10 , 12.5 , 15 mg/kg ) investigate stage 1 . The start dose L-NMMA 7.5 mg/kg . As patient accrue , standard Bayesian model average continual reassessment method ( CRM ) approach use determine appropriate L-NMMA dosage . In stage 2 , start dose one dose level MTD determine stage 1 . Again CRM use determine appropriate L-NMMA dosage . Patients receive 6 ( 21-day ) cycle L-NMMA docetaxel combination . L-NMMA administered via 2-hour intravenous infusion Days 1-5 cycle . Docetaxel administer via 1-hour intravenous infusion approximately 15 minute Day 1 L-NMMA infusion . For L-NMMA-induced hypertension , amlodipine ( 10 mg ) orally administer 6 day cycle . Amlodipine administration start 24 hour first dose L-NMMA . For docetaxel-induced leukopenia , pegfilgrastim ( 6 mg ) administer via subcutaneous injection approximately 24 hour every dose docetaxel . In addition MTD DLT assessment , study also determine recommend phase 2 dose , antitumor activity , pharmacokinetics L-NMMA well explore tissue blood-based marker treatment response toxicity .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>omega-N-Methylarginine</mesh_term>
	<criteria>Patient must meet following criterion : Female patient pathologically determine advanced ( progressive disease refractory 3 cycle standard chemotherapy ) metastatic ( line ) triple negative breast cancer ( TNBC ) . TNBC define : Estrogen receptor negative progesterone receptor negative ( &lt; 10 % stain immunohistochemistry [ IHC ] ) . Human epidermal growth factor receptor 2 ( HER2 ) negative . HER2 negativity must confirm one following : Fluorescence situ hybridization ( FISH ) negative ( FISH ratio &lt; 2 ) , IHC 01+ , IHC 2+ AND FISHnegative ( FISH ratio &lt; 2 ) . Eastern Cooperative Oncology Group performance status ≤ 2 Age ≥ 18 year Laboratory value within follow range : Hemoglobin ≥9.0 g/dL ( transfusion permit ) Absolute neutrophil count ≥1500/mm3 ( 1.5 x 109/L ) Platelet count ≥100,000/mm3 ( 100 x 109/L ) Total bilirubin &lt; 2 X upper limit normal ( ULN ) Creatinine ( Cr ) &lt; 2 X ULN Cr clearance ( CrCl ) ≥30 Cockcroft Gault Alanine transaminase ( ALT ) aspartate transaminase ( AST ) &lt; 2 X ULN ; liver metastases present ALT AST must &lt; 5 X ULN Have adequate organ function ( cardiac ejection fraction ≥ 45 % ) Negative serum pregnancy test within 7 day administration first treatment dose woman childbearing potential ( WOCBP ) . For WOCBP , adequate contraception must use throughout study . For study , acceptable contraception method define Section 12.4 . Ability understand requirement study , provide write informed consent authorization use disclosure protect health information , agree abide study restriction return required assessment . Patient must willing undergo biopsy require study protocol . Biopsies base acceptable clinical risk judge investigator . Tissue previous biopsy accept form tissue slide . History poorly control hypertension ( define systolic blood pressure &gt; 150 mmHg baseline ) Patients metastatic disease receive radiation therapy , chemotherapy , noncytotoxic investigational agent within 2 week study treatment initiation . Patients may receive antineoplastic treatment study followup period . Patients receive docetaxel line treatment within past 12 month Evidence New York Heart Association class III great cardiac disease History myocardial infarction , stroke , ventricular arrhythmia , symptomatic conduction abnormality within past 12 month History congenital QT prolongation Absolute correct QT interval &gt; 460 msec presence potassium &gt; 4.0 mEq/L magnesium &gt; 1.8 mg/dL Any medical psychiatric condition would prevent informed consent limit expect survival less 4 week Symptomatic central nervous system metastases Pregnant nursing woman Hypersensitivity intolerance LNMMA , docetaxel , amlodipine , pegfilgrastim , component Use amlodipine another calcium channel blocker past 14 day Alcoholism hepatic disease exception liver metastasis Severe renal insufficiency ( CrCl &lt; 30 mL/min [ Cockcroft Gault ] ) History gastrointestinal bleeding , ulceration , perforation Concurrent use potent cytochrome P450 ( CYP ) 3A4 inhibitor , ketoconazole , itraconazole , clarithromycin , atanazir , indinavir , nefazodone , neflinavir , ritonavir , saquinavir , telithromycin , voriconazole Concurrent use potent CYP3A4 inducer , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbitol , St. John 's wort . Concurrent use medication interact nitrate/nitrites • Use investigational drug within 14 day precede first dose study medication . Concurrent use complementary alternative medicine Patients &gt; Grade 2 neuropathy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>nitric oxide synthase</keyword>
	<keyword>docetaxel</keyword>
	<keyword>L-NMMA</keyword>
</DOC>